Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients

Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, might predict resistance to endocrine therapy (ET) in patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ breast cancer 2021-06, Vol.7 (1), p.77-77, Article 77
Hauptverfasser: Paoletti, Costanza, Regan, Meredith M., Niman, Samuel M., Dolce, Emily M., Darga, Elizabeth P., Liu, Minetta C., Marcom, P. Kelly, Hart, Lowell L., Smith, John W., Tedesco, Karen L., Amir, Eitan, Krop, Ian E., DeMichele, Angela M., Goodwin, Pamela J., Block, Margaret, Aung, Kimberly, Brown, Martha E., McCormack, Robert T., Hayes, Daniel F.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-endocrine therapy index (CTC-ETI), consisting of CTC-ER (estrogen receptor), BCL2, human epidermal growth factor receptor (HER2), and Ki67 expression, might predict resistance to endocrine therapy (ET) in patients with ER-positive MBC. One hundred twenty-one patients with ER-positive/HER2-negative MBC initiating a new ET after ≥1 lines of ET were enrolled in a prospective, multi-institutional clinical trial. CTC-ETI and clinical/imaging follow-up were performed at baseline and serial time points. Progression-free survival (PFS) and rapid progression (RP; determined at the 3-month time point) were primary endpoints. Associations with clinical outcomes used logrank and Fisher’s exact tests. At baseline, 36% (38/107) of patients had ≥5 CTC/7.5 ml whole blood (WB). Patients with ≥5 vs.
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-021-00281-1